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Itraconazol, um antifúngico de amplo espectro, possui muitos efeitos colaterais e o uso de 
nanossistemas para a entrega de fármacos tem sido proposto como um método para otimizar a 
farmacocinética da droga e reduzir os efeitos colaterais. Um procedimento de cromatografia líquida 
de alta performance (HPLC) utilizando detecção fluorimétrica foi desenvolvido para a determinação 
de itraconazol em nanopartículas do copolímero de ácido láctico e glicólico, plasma e tecidos. A 
linearidade, limites de detecção e quantificação, recuperação, precisão, seletividade e estabilidade 
do método foram estabelecidas. O método desenvolvido foi testado na detecção e quantificação 
de itraconazol na biodistribuição de nanopartículas administrados intraperitonealmente em 
camundongos fêmeas Balb/C. Neste estudo foi desenvolvido um método analítico de HPLC com 
detecção fluorimétrica para quantificação de itraconazole em nanopartículas poliméricas, tecidos e 
plasma, sendo ele sensível, de baixo custo, viável para uso de rotina e com potencial para aplicação 
na biodistribuição e estudos farmacocinéticos de itraconazole em nanossistemas.
Itraconazole, a broad-spectrum anti-fungal, has many side effects, and nanosystems for drug 
delivery have been proposed as a method to optimize the drug’s pharmacokinetics and reduce 
side effects. An high performance liquid chromatography (HPLC) procedure using fluorometric 
detection was developed for determination of itraconazole in polymeric poly(lactic-co-glycolic 
acid) nanoparticles, plasma and tissue. Linearity, limits of detection and quantification, recovery, 
precision, selectivity and stability were established. The developed method was tested in itraconazole 
detection and quantification of biodistribution of nanoparticles administered intraperitoneally to 
Balb/C female mice. This study developed an analytical method for HPLC with fluorometric 
detection for quantification of itraconazole in polymeric nanoparticles, tissue and plasma, which 
is sensitive, low cost, viable for routine usage and with potential for application in itraconazole 
biodistribution and pharmacokinetics studies.
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Introduction
Itraconazole (ITZ) (Figure 1) is a classical member 
of the triazole class that exhibits a broad-spectrum anti-
fungal activity.1 Diverse side effects, such as nausea, 
vomiting, abdominal pain, diarrhea, headaches and mild 
alopecia, commonly identified with ITZ treatment of fungal 
infections,2,3 can be avoided using nanoparticulated drug 
delivery systems.4 Nanosystems can protect drugs from 
degradation and inactivation, allowing the concentration 
needed to obtain therapeutic efficacy to be reduced and 
consequently produce fewer adverse effects.5 One of the 
most important aspects of nanosystems and inclusion 
complexes for drug delivery is the capacity to alter 
pharmacokinetics and biodistribution of drugs in the 
vascular system and on targeted tissue.6-8 Polymeric 
nanosystems have gained increased attention and 
poly(lactic-co-glycolic acid) (PLGA), a polymer from the 
ester family, has wide use in the biomedical industry, since 
by-products of its degradation are nontoxic.9
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Various methods for the quantification of ITZ have 
been developed, with spectrophotometry,10-13 thin layer 
chromatography,14,15 and high performance liquid 
chromatography (HPLC) from diverse matrixes.16-19 Liquid 
chromatographic methods are the most extensively used 
techniques in pharmaceutical analysis, and HPLC has 
gained increased attention for being the most versatile 
technique. It can be used for separation, identification 
and quantification of active substances, excipients and 
impurities.20 Despite its worldwide usage and applications 
in ITZ quantification in diverse nanosystems,21,22 no method 
has yet been developed and validated for determination of 
ITZ of PLGA nanoparticles in biological matrices.
Green analytical chemistry principles should always be 
considered in the development of new analytical methods. 
For liquid chromatographic separations, solvent replacement, 
use of less toxic or less persistent solvents, allied to a 
reduction in solvent usage in all the steps of the procedure, 
are the typical ways used to cut down on products that are 
harmful to human health or the environment.23 
The aim of this study was to develop an environmentally 
friendly bioanalytical method for HPLC with fluorometric 
detection for quantification of ITZ in nanoparticles, plasma, 
lung, liver, kidney and spleen tissue, and that was sensitive, 
low-cost, viable for routine usage and with potential for 
application in ITZ biodistribution and pharmacokinetics 
studies.
The method was validated based on FDA guidelines 
for validation of bioanalytical methods.24 The assay 
performance was evaluated through the determination of 
selectivity, limits of detection (LOD), limits of quantification 
(LOQ), the linearity over the tested concentration range, 
recovery, precision and stability.
Experimental
Chemicals
Itraconazole (R051211-98% purity), dimethyl sulfoxide 
(DMSO-HPLC grade) and zinc sulfate heptahydrate (ACS 
reagent) were purchased from Sigma (Sigma-Aldrich Co., 
St. Louis, MO, USA) and itraconazole internal standard 
(R51012) was purchased from Fitzgerald (Fitzgerald 
Industries International Inc., Concord, MA, USA). 
Acetonitrile (ACN), methanol (MeOH) and tetrahydrofuran 
(THF) used for the HPLC analyses were HPLC grade 
and were purchased from Mallinckrodt (Mallinckrodt 
Inc., Hazelwood, MO, USA). Trifluoracetic acid (TFA), 
ethylenediaminetetraacetic acid (EDTA) and sodium 
cloride (NaCl) were purchased from VETEC (Duque de 
Caxias, RJ, Brazil) and were ACS grade. Milli-Q water 
was obtained from Barnstead EASYpure II Thermo 
Scientific (San Jose, CA, USA) and was used to prepare 
aqueous solutions. DMSA-PLGA nanoparticles loaded 
with itraconazole were synthesized and characterized as 
described by Cunha-Azevedo et al..25
Instrumentation
The chromatographic equipment (Shimadzu-Prominence) 
comprised of on-line degasser (Model DGU 20A5), 
solvent delivery module (Model LC-20AT), autosampler 
(Model SIL-20AHT), column oven (Model CTO-20A), 
fluorescence detector (Model RF-10AXL) and system 
controller CBM-20A. Reverse-phase C18 column ACE AQ 
(25 × 0.4 cm, 5 μm particle size) (ACE, Aberdeen, Scotland) 
with a pre-column (25 × 0.4 cm, 5 μm particle size) (ACE, 
Aberdeen, Scotland) were used. Samples were stored in ultra-
low temperature freezer, Model MDF-U3086S (Sanyo), and 
centrifuged in microcentrifuge model Mikro 220R (Hettich).
Chromatographic condition
The mobile phase was obtained from the mixture of 
0.12% TFA in Milli-Q water (pump A) and 0.12% TFA in 
acetonitrile (pump B) at 50:50 (v/v) proportion, rendering 
an isocratic phase. Fluorimetric measurements were carried 
out in a 12 μL flow cell at 260 and 365 nm excitation and 
emission wavelength respectively. The injection volume was 
10 μL and the flow-rate during the assays was 1 mL min–1 at 
working pressure of 80 kgf cm–2. Analysis was performed 
with column temperature of 30 °C. Software LCsolution 
Figure 1. Chemical structure of itraconazole (1-R051211) and internal 
standard (2-R051012).
Py-Daniel et al. 699Vol. 25, No. 4, 2014
(Shimadzu, Tokyo, Japan) was used for data processing and 
identification of chromatographic parameters.
Extraction and quantification of ITZ in nanoparticles 
ITZ in PLGA-DMSA nanoparticles was extracted 
with DMSO as described by Cunha-Azevedo et al..25 
MeOH, ACN and THF were also used to compare ITZ 
extraction capacity of different solvents. Briefly, aliquots 
of nanoparticles containing ITZ were dissolved in the cited 
solvents (1:1000), sonicated for 10 min, filtered through 
0.22 μm nylon filters (Millex GN, Millipore, Darmstadt, 
Germany) and injected in HPLC system. Filter interference 
in ITZ quantification was determined by comparisons with 
non-filtered centrifuged solutions. Effect in quantification 
of ITZ and IS when diluted in mobile phase or in MeOH 
was also determined.
Animals
Female BALB/c mice weighing 20-22 g were purchased 
from the University of Campinas, São Paulo, Brazil. The 
mice were housed in polypropylene cages under controlled 
conditions of luminosity and were provided with food 
and water ad libitum. All animal procedures performed 
in this study were approved by the Animal Care and Use 
Committee of the University of Brasília (UnB), Brasília, 
Federal District, Brazil.
Biological sample preparation
Plasma, liver, spleen, lung and kidney samples from 
drug-free animals were used as blanks for method validation. 
Blood from anesthetized mice (ketamine 60 mg kg–1 and 
xylazine 7.5 mg kg–1) was collected by heart puncture and 
transferred to tubes containing EDTA. After 30 min at room 
temperature, tubes were centrifuged for 5 min at 5000 g, 
aliquoted and stored at –80 ºC for future analyses. 
For quantification of ITZ in plasma, 0.2 mL of plasma 
were transferred to microcentrifuge tubes with 20 μl of 20% 
ZnSO4 (for protein precipitation),26 mixed in a vortex for 
1 min and extracted with 0.7 mL of MeOH. The samples 
were shaken on a vortex for 3 min and centrifuged for 5 min 
at 6000 g. Supernatant was transferred to a 2 mL volumetric 
flask and 1 mL of MeOH was added to samples to repeat 
extraction. Samples were vortexed for 3 min followed by 
centrifugation for 5 min at 24000 g and transference to 
volumetric flask. 
For ITZ quantification in tissue, organs were removed, 
washed with cold 0.9% NaCl solution, blotted on filter 
paper, weighed and stored at –80 ºC for future analyses. 
Whole organs and 400 mg of liver were homogenized 
in 1.5 mL microcentrifuge tubes with hand pestles and 
extracted using the same process as described for plasma. 
Previous to extraction of plasma and tissue, 40 μL of 
itraconazole internal standard (20 μg mL–1) was added to 
the tubes.
Method development
A stock solution (1 mg mL–1) of ITZ was prepared in 
tetrahydrofuran and itraconazole internal standard (IS) 
(1 mg mL–1) was prepared in MeOH. Solutions of ITZ 
(500, 100, 25, 5 and 1 μg mL–1) and IS (20 μg mL–1) were 
prepared as standards and quality control samples (QC) 
for quantification in biological matrices. Calibration curve 
standards were prepared in mobile phase and in biological 
matrices. Curves in mobile phase were constructed using 
ITZ concentrations of 10, 5, 2, 1, 0.5, 0.2, 0.1, 0.05, 0.02 
and 0.01 μg mL–1 and in biological matrices using ITZ 
concentrations of 10, 2, 0.5, 0.1 and 0.02 μg mL–1 with 
internal standard concentration of 0.4 μg mL–1. Calibration 
curve in mobile phase was obtained by the serial dilution 
method from the stock solution and areas of ITZ observed 
in chromatograms were used. Calibration curves in 
biological matrices were obtained by doping tissue with 
cited concentrations of ITZ and IS, followed by extraction 
as described in topic Biological sample preparation. The 
ratio of areas of ITZ and IS obtained on chromatograms was 
used to construct calibration curves with internal standard 
in biological matrix.
The bioanalytical method was also used to determine 
ITZ concentrations in plasma, liver, kidney, spleen and lung 
samples of healthy mice (n = 3). The mice received 300 μL 
of single intraperitoneal doses of 200 μg mL–1 ITZ-loaded, 
PLGA nanoparticles. Blood samples (approximately 
800 μL) were collected by heart puncture in VACUETTE® 
K3E K3EDTA tubes (Greiner Bio-One) one hour after 
administration. Samples were centrifuged after 30 min for 
5 min at 500 g, and the plasma was then frozen at −80 °C 
until analysis. After euthanasia of the mice, tissues of 
interest were excised, washed with cold saline and blotted 
on filter paper. The quantification of ITZ in biological 
samples was undertaken within 72 h post-collection of 
samples using the method described above.
Method validation
Linearity
The data, area (ITZ) vs. ITZ known concentration, were 
fitted to a linear equation (y = mx + b) and the regression 
parameters and determination coefficient (r2) calculated. 
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Limit of detection and limit of quantification
The limit of detection was determined as 3.3*(standard 
deviation)/(slope of analytical curve) and limit of 
quantification as 10*(standard deviation)/(slope of 
analytical curve),27 considering the standard deviation of the 
lowest concentration of ITZ used in the calibration curve. 
Recovery
Recovery of the method (%) was obtained by comparison 
of observed values of ITZ/IS in processed matrix with 
standard solutions of ITZ/IS containing the same added 
concentration. Intra-day recovery was determined by 
analysis of three replicates of low, medium and high (0.01, 
1 and 10 μg mL–1, respectively) concentrations of ITZ and 
IS (0.4 μg mL–1) in liver, lung, spleen, kidney and plasma 
in the same day. Inter-day recovery was determined by the 
analysis of different processed samples on three different 
days.
Precision
Intra-day precision was determined by analysis of three 
replicates of low, medium and high (0.01, 1 and 10 μg mL–1, 
respectively) concentrations of ITZ and IS (0.4 μg mL–1) 
in liver, lung, spleen, kidney and plasma in the same day. 
Inter-day precision was determined by the analysis of 
different processed samples on three different days. The 
precision of the method was expressed as relative standard 
deviation (RSD) of ITZ/IS areas in processed matrices in 
the cited concentrations.
Selectivity
Selectivity of the method was investigated by processing 
and analyzing blank plasma and tissues from three animals 
with and without addition of ITZ/IS. Selectivity is 
established as absence of peaks in blank samples at the 
same retention time of ITZ and IS.
Stability 
Stability of ITZ and IS in methanol was determined by 
daily quantification of solutions maintained at –20 °C and 
at 25 °C with low, medium and high concentrations of ITZ 
(0.01, 1 and 10 μg mL–1, respectively) and IS (0.4 μg mL–1). 
Samples were verified for seven days, maximum time 
proposed for sample processing.
Results and Discussion
Optimum mobile phase composition was determined 
by analysis of ITZ and IS peaks in water/solvent gradients 
in a standard C-18 column. The composition, acetonitrile/
water with trifluoracetic acid with gradient elution, allowed 
modulation of mobile phase strength and optimization of 
retention time of ITZ and IS. The retention time of ITZ and 
IS was decisive for definition of isocratic mobile phase used 
throughout experiments: acetonitrile: water (50:50, with 
0.12% TFA). Injection volume was defined by optimum 
signal range/sensitivity factors and was established in 10 μL, 
since this volume resulted in a wide range of concentrations 
detectable in the same method (10-0.01 μg mL–1) with high 
sensitivity. Injection volumes of 5 and 20 μL were also 
tested with solutions with concentrations ranging from 
10-0.01 μg mL–1, but the dynamic range was always smaller. 
Using the developed analytical method, ITZ retention time 
was 7.6 min and internal standard retention time was 9.1 
min with 11 min for each run. With the conditions obtained, 
the typical chromatographic parameters: retention time, 
retention factor (k’), separation factor (α), resolution (Re), 
number of plates (N), height of theoretical plates (H) and 
suitability were calculated for each compound (Table 1). 
Suitability was determined as relative standard deviation of 
areas of peaks of consecutive injections of ITS and IS stock 
solution (0.1 μg mL–1 and 0.4 μg mL–1, respectively) (n = 6).
The parameters values demonstrated: 1) adequate 
interaction with the column, 2) ideal separation of peaks 
of itraconazole and internal standard, and 3) symmetric 
shape of the peaks obtained. 
Solvent extraction of ITZ from nanoparticles and tissue 
aimed at low cost-high output extraction procedure. The 
efficiency of different solvents in ITZ extraction from 
nanoparticles was determined by comparison with DMSO 
extraction, because DMSO is the solvent used for the 
drug encapsulation efficiency calculation in nanoparticle 
characterization.24 MeOH, DMSO and THF rendered 
the same extraction capacity, and for practical reasons, 
Table 1. Chromatographic parameters of itraconazole and internal standard in described method
Standard / 
(μg mL–1) tr / min k’ Re α N H / μm T
Suitability / 
(RSD%)
Itraconazole 0.1 7.6 1.6 10.00a 1.4 9563 26 1.1 0.31%
Internal standard 0.4 9.1 2.2 4.7b – 10691 23 1.1 0.58%
tr: retention time; k’: retention factor; Re: resolution; α: separation factor; N: number of plates; H: height of theoretical plates; T: tailing factor; aresolution 
correlated to dead volume peak; bresolution correlated to itraconazole peak.
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MeOH was used throughout all extraction procedures. No 
difference was observed in the ITZ fluorescent signal when 
the drug was dissolved in mobile phase or MeOH, rendering 
unnecessary solvent substitution from extracted ITZ. 
Calibration curves in mobile phase and in biological 
matrices resulted in the values observed in Table 2. For 
construction of each point of the calibration curve in mobile 
phase triplicates of peak areas were used. Over the range 
of 10-0.02 μg mL–1 for biological matrices and 10-0.2 and 
0.2-0.001 μg mL–1 in mobile phase, the linear fit was used 
and correlation coefficients were obtained (Table 2).
The limits of detection (LOD) and quantification (LOQ) 
were determined (Table 2), and results are in agreement 
with the targeted application of the method: the value of 
the limit of detection obtained demonstrates sensitivity 
that permits dosage of ITZ in probable low concentrations 
throughout biodistribution studies. Calibration curves for 
ITZ and IS ratio in biological matrix can be seen in Table 3.
Recovery and precision of extractions from doped plasma 
and tissue may be observed in Table 4. The recovery varied 
between 83 and 106%. The extraction procedure was the 
same for all tested matrices and demonstrated satisfactory 
and rapid extraction of ITZ. It is worth noting that only 
one solvent was used without purification or substitution, 
rendering a low-cost and fast method. The precision observed 
for the analytical procedure developed expresses a close 
agreement between a series of measurements obtained from 
multiple sampling of a homogeneous sample. Intra-day and 
inter-day precision and recovery of plasma, lung, kidney, 
spleen and liver are presented in Table 4.
No interfering peaks were found at the retention time of 
the analyzed drug and internal standard, demonstrating the 
selectivity of the method (Figure 2). The chromatographic 
runs were completed at 11 min, a short run when compared 
to most methods for ITZ quantification in HPLC,28 resulting 
in less waste, in accordance with the principles of green 
analytical chemistry.23
Stability of quality control samples maintained as 25 °C 
demonstrated by the seventh day degradation of 23%, 15% 
and 17% of low, medium and high concentration while all 
samples kept at –20 °C varied in less than 0.05% of initial 
concentration. This result demonstrates that processed 
samples can be stored for one week without degradation 
of ITZ.
Application of bioanalytical method
The bioanalytical method was tested for ITZ 
quantification in organs and plasma after administration 
of nanoparticles in mice. One hour after intraperitoneal 
injection, organs were extracted and processed as described 
earlier. The result of percentage of injected drug per gram 
Table 2. Linear regression parameter and limits of detection and quantification for itraconazole (area vs. concentration)
Calibration curves Range of concentration / (μg mL–1)
Parameter of curve LOD /
(μg mL–1)
LOQ /
(μg mL–1)Slope Intercept r2
Mobile phase 10-0.20 720801 –4366.1 0.9992 0.151 0.459
Mobile phase 0.2-0.01 780523 297.6 0.9999 0.003 0.008
Kidney 10-0.02 707156 14640 0.9996 0.001 0.004
Liver 10-0.02 642671 5640 0.9994 0.007 0.020
Lung 10-0.02 691500 11502 0.9999 0.009 0.026
Spleen 10-0.02 646530 12203 0.9999 0.020 0.061
Plasma 10-0.02 653569 12560 0.9998 0.039 0.117
r2: determination coefficient; LOD: limit of detection; LOQ: limit of quantification.
Table 3. Linear regression parameters for itraconazole/itraconazole internal standard (ITZ/IS) curve
Range of concentration / (μg mL–1)
Parameter of curve
Slope Intercept Determination coefficient (r2)
Kidney 10-0.02 3.7119 0.0849 0.9996
Liver 10-0.02 4.2484 –0.1666 0.9998
Lung 10-0.02 3.288 0.1317 0.9999
Spleen 10-0.02 3.5952 –0.0384 0.9999
Plasma 10-0.02 3.5539 0.0293 0.9996
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of tissue is shown in Table 5. The method demonstrated fast 
and effective capacity of ITZ dosing in tissue and plasma 
after nanoparticle administration and calibration curves in 
matrixes with the ITZ/IS reason rendered a method that 
normalizes losses in extraction procedures. 
The proposed method was described and validated 
for ITZ extraction for biodistribution/pharmacokinetic 
studies, but serves as a model for future development 
of methods for extraction of lipophilic drugs from 
nanosystems and tissue. The cited advantages of HPLC 
for routine detection and quantification more than justify 
its usage in such studies, as well as the growing demand 
for validated, efficient and rapid methods for application 
in nanotechnology.
Table 4. Precision and recovery of intra-day and inter-day itraconazole extraction in biological matrices (n = 3)
Tissue Concentration / (μg mL–1)
Precision (RSD%) Recovery / %
Intra-daya Inter-daya Intra-day Inter-day
Plasma
0.01 14.36 5.11 83.24 105.73
1 4.50 1.57 103.42 100.52
10 1.41 1.81 95.46 99.32
Liver
0.01 8.13 14.92 105.23 102.96
1 3.91 1.13 93.47 95.56
10 2.78 1.38 99.94 105.16
Lung
0.01 5.21 7.95 105.01 85.25
1 1.72 3.75 100.09 97.32
10 5.43 2.21 93.10 99.61
Kidney
0.01 7.94 12.92 88.72 108.25
1 3.95 2.51 94.72 99.41
10 4.75 0.71 96.94 102.69
Spleen
0.01 10.24 5.74 103.41 96.33
1 1.58 0.68 97.82 97.48
10 7.15 1.75 95.14 104.64
RSD = Relative standard deviation; aintra-day = day 1; inter-day = days 1, 2 and 3.
Figure 2. Chromatogram of blank and spiked samples (ITZ = 0.5 μg mL–1, IS = 0.4 μg mL–1) of tissues and plasma. 
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Conclusion
An HPLC method with isocratic elution and fluorescent 
detection was developed for ITZ determination in 
polymeric nanoparticles and biological samples. Only one 
solvent was used in a liquid-liquid extraction with no need 
of drying or concentrating of samples, resulting in time 
gained in process. The method was simple, low-cost and 
environmentally friendly, using only MeOH for extraction 
of itraconazole in samples. Low limits of detection and 
quantification were observed. The validated method permits 
the identification and quantification of ITZ in virtually 
all staged of nanoparticle preparation with an adequate 
precision and recovery. Preliminary biodistribution of 
itraconazole showed good applicability for biodistribution 
and pharmacokinetic studies. 
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Table 5. Determination of ITZ in organs and plasma after 1 h of 
intraperitoneal administration of nanoparticles containing ITZ (n = 3)
Sample % dose × (g of tissue)–1
Kidney 0.35 0.37 0.46
Liver 7.46 7.26 6.01
Lung 51.90 69.78 66.38
Spleen 14.85 15.10 11.52
% dose × (total plasma)–1
Plasma 0.12 0.02 0.05
